18F-氟脱氧葡萄糖正电子发射断层显像诊断副肿瘤性神经综合征患者恶性肿瘤的系统评价与荟萃分析
该系统评价与荟萃分析纳入16项研究共793例疑似副肿瘤性神经综合征(PNS)患者,评估FDG PET检测潜在恶性肿瘤的诊断性能,合并灵敏度为0.87(95%CI 0.80-0.93)、特异度为0.86(95%CI 0.83-0.89)、恶性肿瘤检出率为14.9%(95%CI 11.5-18.7),汇总ROC曲线下面积为0.917;作者结论认为FDG PET对PNS相关恶性肿瘤具有较高诊断性能,且不受副肿瘤神经抗体或临床特征影响。
要点
- FDG PET检测PNS相关恶性肿瘤的合并灵敏度为0.87、特异度为0.86。
- 16项研究共793例患者,恶性肿瘤检出率为14.9%(95%CI 11.5-18.7)。
- 汇总ROC曲线下面积为0.917,灵敏度结果同质但特异度不同质。
核心结论
- 作者结论认为FDG PET在检测PNS相关恶性肿瘤方面具有较高诊断性能,且不受副肿瘤神经抗体或临床特征影响。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、EMBASE、Cochrane和DARE数据库,纳入任何语言发表的研究。
- 检索策略按PICO框架围绕该检查的有效性或实用性临床问题构建。
- 纳入标准为涉及PNS患者、行FDG PET检测恶性肿瘤并报告足够原始数据以计算诊断准确性参数的研究。
- 最终纳入16项研究,其中12项为回顾性研究,共793例患者。
- 采用QUADAS-2工具评估偏倚风险。
主要发现
- 16项研究共793例患者,FDG PET检测恶性肿瘤的合并灵敏度为0.87(95%CI 0.80-0.93)。
- 合并特异度为0.86(95%CI 0.83-0.89)。
- 恶性肿瘤检出率为14.9%(95%CI 11.5-18.7)。
- 汇总ROC曲线下面积为0.917。
- 灵敏度结果同质,特异度结果不同质;部分单个研究因样本量小出现较宽的95%CI。
关键数值与推荐
- 合并灵敏度0.87(95%CI 0.80-0.93),合并特异度0.86(95%CI 0.83-0.89),恶性肿瘤检出率14.9%(95%CI 11.5-18.7),AUC 0.917。
- 亚组分析基于患者特征(抗体、综合征)进行,但原文未报告亚组具体数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 多数研究为回顾性研究(12/16)。
- 部分单个研究因样本量小出现较宽的95%CI。
- 特异度结果不同质。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The detection of occult cancer in patients suspected of having a paraneoplastic neurological syndrome (PNS) poses a diagnostic challenge. The aim of our study was to perform a systematic review and meta-analysis to assess the diagnostic performance of FDG PET for the detection of occult malignant disease responsible for PNS. METHODS: A systematic review of the literature (MEDLINE, EMBASE, Cochrane, and DARE) was undertaken to identify studies published in any language. The search strategy was structured after addressing clinical questions regarding the validity or usefulness of the test, following the PICO framework. Inclusion criteria were studies involving patients with PNS in whom FDG PET was performed to detect malignancy, and which reported sufficient primary data to allow calculation of diagnostic accuracy parameters. When possible, a meta-analysis was performed to calculate the joint sensitivity, specificity, and detection rate for malignancy (with 95% confidence intervals [CIs]), as well as a subgroup analysis based on patient characteristics (antibodies, syndrome). RESULTS: The comprehensive literature search revealed 700 references. Sixteen studies met the inclusion criteria and were ultimately selected. Most of the studies were retrospective (12/16). For the quality assessment, the QUADAS-2 tool was applied to assess the risk of bias. Across 16 studies (793 patients), the joint sensitivity, specificity, and detection rate for malignancy with FDG PET were 0.87 (95% CI: 0.80-0.93), 0.86 (95% CI: 0.83-0.89), and 14.9% (95% CI: 11.5-18.7), respectively. The area under the curve (AUC) of the summary ROC curve was 0.917. Homogeneity of results was observed for sensitivity but not for specificity. Some of the individual studies showed large 95% CIs as a result of small sample size. CONCLUSIONS: The results of our meta-analysis reveal high diagnostic performance of FDG PET in the detection of malignancy responsible for PNS, not affected by the presence of onconeural antibodies or clinical characteristics.
引用
- García Vicente AM, Delgado-Bolton RC, Amo-Salas M, et al. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of malignancy in patients with paraneoplastic neurological syndrome: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2017. PMID: 28550611. doi:10.1007/s00259-017-3722-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。